DDInter413 DDInter1435
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Clopidogrel {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Clopidogrel {u} (Compound) treats {v} (Disease) coronary artery disease
Clopidogrel {u} (Compound) binds {v} (Gene) P2RY12
Clopidogrel {u} (Compound) upregulates {v} (Gene) TBXA2R
Clopidogrel {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Clopidogrel {u} (Compound) downregulates {v} (Gene) DECR1
Clopidogrel {u} (Compound) causes {v} (Side Effect) Deafness
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluvastatin
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Modafinil
Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Clopidogrel (Compound) treats coronary artery disease (Disease)
Clopidogrel (Compound) binds P2RY12 (Gene)
Clopidogrel (Compound) upregulates TBXA2R (Gene)
Clopidogrel (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Clopidogrel (Compound) downregulates DECR1 (Gene)
Clopidogrel (Compound) causes Deafness (Side Effect)
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fluvastatin
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Torasemide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Modafinil